Biogen sees negative Q2 impact from IPR&D, milestone expenses

 

• Biogen said it will incur a $46M charge in its Q2 results leading to a ($0.26) impact in its GAAP and non-GAAP EPS due to acquired in-process research and development (IPR&D), upfront, and milestone expenses.
• The biotech said it began listing those expenses as a separate line item in its income statement in Q1. These costs relate to "collaboration and license agreements such as upfront and milestone payments and, when applicable, premiums on equity securities and asset acquisitions of acquired in-process research and development."
• EPS consensus estimates for Q2 are $3.23 on a GAAP basis, and $4.06 on a non-GAAP basis. The quarterly earnings release is scheduled for July 31 before market open. 

https://www.msn.com/en-us/money/savingandinvesting/biogen-sees-negative-q2-impact-from-ipr-d-milestone-expenses/ar-AA1I943T